NARA Discovery
Article Details
← Back to Search Results
Journal Article

Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans

Janardan P. Pandey; Paul J. Nietert; Aryan M. Namboodiri; David A. Bennett; Lisa L. Barnes
Immunogenetics · Vol. 77, Issue 1 · 2025

Abstract

Genome-wide association studies (GWAS) of Alzheimer’s disease (AD) have identified a large number of susceptibility genes, but most of AD heritability remains unexplained, implying the existence of additional genes. Furthermore, the majority of the GWAS have been conducted in people of European descent, and the genes important for AD susceptibility in people of African descent have been underexplored. In this hypothesis-generating prospective cohort study, we genotyped 191 African Americans (AAs) from three longitudinal cohorts on aging for the IgG3 allotype GM6, which is expressed exclusively in people of African descent, and assessed its interaction with IGHG , FCGRIIB , and HLA-DRB1 genes. Cox proportional hazards modeling showed that GM6 by itself was not significantly associated with AD development. However, there was evidence of epistatic interaction: The risk of developing AD associated with GM6 positivity was significantly different ( p = 0.0098) in non-GM17/GM17 participants compared with GM 17/GM17 participants. Specifically, in non-GM17/GM17 participants, the risk of AD was over fourfold higher in GM6-positive participants compared with GM 6-negative participants (HR = 4.63). Similarly, risk of developing AD associated with GM6 positivity was marginally different in non-FCGRIIB TT participants compared with FCGRIIB TT participants. In non-FCGRIIB TT participants, the risk of developing AD was over twofold higher in GM6-positive participants compared with GM6-negative participants (HR = 2.44). This is the first report suggesting that immunoglobulin GM allotypes might play a role in AD etiology among AAs; however, since this was largely a hypothesis-generating study, replication in larger cohorts would be required to confirm this finding.

Bibliographic Information

JournalImmunogenetics
PublisherSpringer
Publication Date2025-12-01
Publication Year2025
Volume77
Issue1
Document TypeJournal Article
eISSN1432-1211
DOI10.1007/s00251-024-01358-4

Access Information

NARA Access Coverage1974-01-01~Current
Journal Homepagehttps://www.springer.com/journal/251
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.